CureMD Oncology Integrates NCCN TemplatesNew York, NY. 5/30/2019
PLYMOUTH MEETING, PA [May 28, 2019] — The National Comprehensive Cancer Network® (NCCN®) is collaborating with CureMD to integrate the NCCN Chemotherapy Order Templates (NCCN Templates®) into the CureMD Oncology EHR to allow for point-of-care access to treatment recommendations and order templates derived from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).
“The collaboration with CureMD advances NCCN’s commitment to supporting evidence-based clinical decision support to improve quality, safety and ultimately outcomes in cancer care,” said C. Lyn Fitzgerald, MJ, Senior Vice President, U.S. & Global Development, NCCN. “We’re enthusiastic about the inclusion of the NCCN Guidelines and NCCN Templates in the CureMD Oncology EHR platform as it will make it easier for clinicians to provide the best evidence- and expert-consensus-based decisions for their patients.”
CureMD is a leading provider of innovative health information systems and services that transform the administrative and clinical operations of healthcare organizations. Their oncology EHR automates providers’ workflows and includes key features that ensure oncology practices and their patients have access to evidence-based treatment information developed by leading experts in the field.
“At CureMD Oncology, we are dedicated to elevating the level of care oncology practices provide cancer patients. Collaborating with NCCN and providing oncology practices with industry-leading clinical guidelines and treatment regimens through our award-winning Oncology EHR is a resounding example of our dedication to improving care quality,” said Bill Hashmat, CEO, CureMD.
The NCCN Guidelines are the recognized standard for clinical policy in cancer care and are the most thorough and most frequently updated clinical practice guidelines available in any area of medicine. Derived directly from the NCCN Guidelines, the NCCN Templates® include chemotherapy and immunotherapy regimens with literature support, supportive care agents, monitoring parameters and safety instructions. The goal of the NCCN Templates is to enhance patient safety by empowering health care providers to standardize patient care, reduce medical errors, and anticipate and manage adverse events.
NCCN continues to add to the library of chemotherapy order templates to improve the safe use of drugs and biologics in cancer care.
For more information about the use of NCCN Content in Health Information Technology, visit NCCN.org/HIT.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 28 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world.
The NCCN Member Institutions are: Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA; Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope National Medical Center, Duarte, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; O'Neal Comprehensive Cancer Center at UAB, Birmingham, AL; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Rogel Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.